Evidence map›Paper›PMID 40265853›Full record

ReviewPlants (Basel, Switzerland)2025

Natural Products for Melanoma Therapy: From Traditional Medicine to Modern Drug Discovery.

Soojin An, Jeongeun An, Dain Lee, Han Na Kang, Sojin Kang, Chi-Hoon Ahn, Rony Abdi Syahputra, Rosy Iara Maciel A Ribeiro, Bonglee Kim

Abstract readReview
In one paragraph

Review in Plants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Bioactive Potential ofPlants (Basel, Switzerland) · 2025
    Article
  6. Plants (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Soojin AnCollege of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0009-0002-5567-6385
Jeongeun AnCollege of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0009-0009-3016-8158
Dain LeeCollege of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
Han Na KangKM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.ORCID 0009-0006-5022-774X
Sojin KangCollege of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0009-0009-4479-8724
Chi-Hoon AhnCollege of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0000-0003-3643-0566
Rony Abdi SyahputraDepartment of Biological Sciences, State Islamic University of Sunan Kalijaga (UIN Sunan Kalijaga), Yogyakarta 55281, Indonesia.ORCID 0000-0003-2016-0151
Rosy Iara Maciel A RibeiroLaboratory of Experimental Pathology, Federal University of São João del Rei-CCO/UFSJ, Divinópolis 35501-296, Brazil.ORCID 0000-0002-7374-4743
Bonglee KimCollege of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0000-0002-8678-156X

Funding

grant of the Korea Health Technology R&D Pro-ject through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea RS-2020-KH087790Korea government (MSIT)-National Research Foundation of Korea No. 2020R1A5A2019413Korea government (MSIT)-National Research Foundation of Korea RS-2021- R1C1C2014229Korea government (MSIT)-National Research Foundation of Korea RS-2024-00350362Ministry of Education-National Research Foundation of Korea NRF-2020R1I1A2066868
6 · The paper itself

Abstract

Melanoma, a type of skin cancer originating from melanocytes, represents a significant public health concern according to the World Health Organization. It is one of the most commonly diagnosed cancers worldwide, particularly affecting populations in Europe and North America, with an increasing incidence in Asia. The rise emphasizes the need for diversified treatment approaches. Conventional treatments for melanoma, including immunotherapy, chemotherapy, and targeted therapies like the FDA-approved Opdivo and Relatlimab, often come with severe side effects and high relapse rates. Consequently, natural products have gained considerable attention for their potential to enhance therapeutic outcomes and reduce adverse effects. This systematic review evaluates the anti-cancer properties of natural products against melanoma, examining 52 studies from PubMed and Google Scholar. Our analysis focuses on the antioxidant, anti-angiogenesis, anti-metastatic, and apoptosis-inducing activities of these compounds, also discussing the regulatory factors involved. The findings advocate for intensified research into natural products as complementary agents in melanoma treatment, aiming to improve efficacy and patient quality of life. Further in vitro, in vivo, and clinical trials are essential to validate their effectiveness and integrate them into standard care protocols.

Indexed as

angiogenesisanti-cancerantioxidantapoptosismelanomametastasisnatural productsreactive oxygen species (ROS)

Identifiers

PMID40265853
PMCPMC11946750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.